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Expression of the costimulatory molecule B7-H4, a member of the inhibitory B7 family, 
has been reported to be upregulated on tumor-associated macrophages, and this overex-
pression may be involved in immune evasion in cancer patients.  The present study was 
designed to investigate B7-H4 expression on monocytes/macrophages and its relationship 
with immune evasion in gastric cancer patients.  B7-H4 expression on circulating mono-
cytes and tumor-associated macrophages was evaluated by multicolor flow cytometry. 
Carboxyfluorescein succinimidyl ester proliferation assays and quantitative interferon-
gamma enzyme-linked immunosorbent assays were carried out to determine the inhibitory 
effect of B7-H4+ monocytes on CD4+ T cells.  B7-H4 expression on circulating monocytes 
was upregulated and these B7-H4+ monocytes showed immunosuppressive properties.  B7-
H4 expression was closely related to the depth of invasion, as well as the presence of lym-
phatic and venous invasion.  There were significant correlations between B7-H4 expression 
and B7-H1 or HLA-DR expression on monocytes/macrophages in gastric cancer patients. 
B7-H4 expression was remarkably upregulated in gastric cancer tissues compared with pe-
ripheral blood samples.  Complete surgical removal of the tumor decreased B7-H4 expres-
sion on circulating monocytes from gastric cancer patients.  Cocultures of gastric cancer 
cell lines and monocytes led to upregulation of B7-H4 expression on monocytes.  Increased 
B7-H4 expression on circulating monocytes and tumor-associated macrophages may be 
one of the key mechanisms responsible for immune evasion by tumors in gastric cancer.
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The last 2 decades of research in the cancer immu-
nology field have revealed that the majority of can-
cer cells express antigens that can be recognized by 
T cells of the host immune system.  However, de-
spite the expression of these antigens, spontaneous 
immune-mediated rejection of cancer cells seems 
to be a rare event.  The failure of spontaneous 
immune-mediated tumor elimination can generally 
be explained by poor T-cell priming or inadequate 
execution of the effector phase of the immune re-
sponse.  In each of these contexts, potential roles 
for T-cell costimulatory and coinhibitory receptors 
have been suggested.
 T lymphocytes are thought to play an impor-
tant role in the control of tumors as a result of their 
cytotoxic activity and by releasing soluble factors. 
Optimal activation of T cells requires at least 2 
signals, namely antigen recognition and costimula-
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tion.  T cell receptor complexes, which recognize 
antigenic peptides presented by major histocom-
patibility complex (MHC) molecules, are critical 
for maintaining the specificity of the immune re-
sponse.  Costimulation is an antigen-independent 
signal required for sustained cell proliferation, 
effector/memory cell generation and prevention of 
anergy or apoptosis, and can be either positive or 
inhibitory.  Positive costimulation can enhance T 
and B cell activation, while inhibitory costimula-
tion can just as strongly attenuate these responses. 
The final outcome of an immune response is likely 
to depend on the balance between these positive 
and negative signals (Driessens et al., 2009).  The 
expression of costimulatory molecules is restricted 
to professional antigen-presenting cells, such as 
dendritic cells, macrophages and monocytes.  The 
B7 family comprises such costimulatory molecules 
and consists of both stimulatory and inhibitory 
molecules (Carreno and Collins, 2002; Greenwald 
et al., 2002; Liang and Sha, 2002; Chen, 2004; 
Driessens et al., 2009).  Signals mediated by the 
B7 family members result in T-cell suppression 
or activation in different settings.  B7-1 and B7-2 
are 2 identified stimulatory B7 family members, 
while B7-H1 and B7-H4 are 2 identified inhibitory 
B7 family members (Chen, 2004).  Since the final 
outcome of an immune response is likely to depend 
on the balance between these positive and negative 
signals, it is possible that overexpression of inhibi-
tory B7 family members induces immunosuppres-
sion through the suppression of T cell function.  In 
fact, previous studies have demonstrated that both 
ovarian cancer and ovarian cancer-associated my-
eloid dendritic cells express B7-H1 and that these 
B7-H1+ cancer cells and myeloid dendritic cells 
reduce tumor-associated antigen (TAA)-specific T-
cell immunity through distinct mechanisms (Dong 
et al., 2002; Curiel et al., 2003).  With regard to 
B7-H4, several research groups have shown that 
human ovarian cancers express high levels of B7-
H4 protein (Choi et al., 2003; Salceda et al., 2005; 
Bignotti et al., 2006; Kryczek, Zou et al., 2006; 
Simon et al., 2006; Tringler et al., 2006).  In ad-
dition, high levels of B7-H4 were detected in non-
small-cell lung cancer (Sun et al., 2006), ductal and 
lobular breast cancer (Salceda et al., 2005; Tringler 
et al., 2005) and renal cell carcinoma (Krambeck et 
al., 2006).  Moreover, Kryczek et al. demonstrated 
that human ovarian cancer-associated B7-H4+ 
macrophages inhibited TAA-specific T-cell immu-
nity, in part through B7-H4 (Kryczek et al., 2006). 
These accumulating lines of evidence suggest the 
possibility that inhibitory B7 family members, 
including B7-H1 and B7-H4, are closely related to 
immune evasion in cancer patients.
 Gastric cancer is one of the most common 
cancers in Asia and its mortality rate still ranks 
second among all cancer deaths worldwide (Parkin 
et al., 2005).  Despite the expression of tumor re-
jection antigens such as MAGE 1–3 (Inoue et al., 
1995) and the presence of tumor-specific cytotoxic 
T cells (Hoshino et al., 1997), the immune system 
fails to exhibit immune responses against gastric 
carcinoma cells, similar to the case for other cancer 
cells.  However, the mechanisms for how gastric 
cancer cells overcome the antitumor immunologi-
cal responses are poorly understood.  Therefore, we 
undertook the present study to determine the ex-
pression of B7-H4 as well as B7-H1 on circulating 
monocytes and tumor-associated macrophages to 
clarify one of the possible mechanisms responsible 
for immune evasion in gastric cancer patients.
 
 
Materials and Methods
 
Patients and normal donors
 
Forty-three patients (29 males and 14 females) who 
were treated at Tottori University Hospital and 
pathologically diagnosed as gastric cancer were en-
rolled in this study.  None of the patients received 
radiotherapy, chemotherapy or other medical inter-
ventions before surgery.  The patients’ characteris-
tics are shown in Table 1.  Healthy controls (n = 18; 
13 males and 5 females) who were treated at Tottori 
University Hospital and diagnosed as inguinal her-
nia or cholelithiasis were age-matched (67.9 ± 10.9 
years for the controls versus 67.6 ± 8.9 years for the 
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patients), and each experiment was performed in 
parallel for the patients and healthy controls.  The 
clinicopathological findings were determined ac-
cording to the Japanese Classification of Gastric 
Carcinoma (Japanese Gastric Cancer Association, 
1998).
 
Preparation of PBMCs 
 
Peripheral blood mononuclear cells (PBMCs) were 
prepared by drawing a 30-mL peripheral blood 
sample from each of the controls or from the pa-
tients before surgery and centrifuged through a 
Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradi-
ent.  Informed consent was obtained from all the 
subjects before blood donation.
 
Isolation of tumor-infiltrating lymphocytes 
 
Freshly excised tumor tissues were minced and 
then digested with 1.5 mg/mL of collagenase D 
(Wako Pure Chemical Industries, Osaka, Japan). 
The resulting cell suspensions were filtered through 
a mesh filter (BD Falcon, Franklin Lakes, NJ).
 
Flow cytometry analysis
 
Fluorescence-activated cell sorting (FACS) analy-
sis was performed using a FACSCalibur (Becton 
Dickinson, Franklin Lakes, NJ).  The follow-
ing antibodies were used to classify the cells: 
anti-CD3-PE-Cy5, anti-CD14-FITC, anti-HLA-
DE-PE, anti-B7-H1-PE and anti-B7-H4-PE (BD 
PharMingen, Franklin Lakes, NJ).
 
Measurement of IFN-gamma concentrations
 
The interferon (IFN)-gamma concentrations were 
measured by enzyme-linked immunosorbent assay 
(ELISA) using a Human IFN-gamma ELISA Kit 
(R&D Systems, Minneapolis, MN). 
 
Media
 
A complete culture medium consisting of RPMI 
1640 (Gibco-BRL, Grand Island, NY), 1% l-
glutamine (Invitrogen, Carlsbad, CA), 1% penicil-
lin/streptomycin (Invitrogen), 2.5% HEPES buffer 
solution (Gibco-BRL), 1% sodium pyruvate (Sigma-
Aldrich, St. Louis, MO), 1% essential amino acids 
(Sigma-Aldrich) and 10% heat-inactivated fetal 
calf serum (Thermo Trace, Melbourne, Australia) 
was used.  For T-cell cultures, fetal calf serum was 
replaced with 10% human AB serum (Gemini Bio-
Products, Woodlands, CA).
 
Cell lines
 
The gastric cancer cell lines MKN-45 and MKN-
74 were purchased from the RIKEN Cell Bank 
(Tsukuba, Japan).
Table 1.  B7-H4 expression on circulating mono-
cytes and clinicopathologic characteristics in 
gastric cancer patients
 Number  B7-H4  P value
 of patients   
Histopathology*
 Differentiated 18 3.5 ± 2.2 
0.255
 Undifferentiated 25 6.1 ± 5.7 
Depth of invasion†
 T1 (early) 23 2.9 ± 2.1 
0.0008
 T2/T3/T4 (advanced) 20 7.4 ± 5.7 
Lymph node metastasis 
 Absent 30 4.4 ± 4.6 
0.098
 Present 13 6.3 ± 4.9 
Lymphatic invasion
 Absent  9 2.4 ± 1.4 
0.03
 Present 34 5.7 ± 5.1 
Vascular invasion
 Absent 12 2.4 ± 1.3 
0.015
 Present 31 6.1 ± 5.2 
Stage
 I 31 5.2 ± 4.8 
0.44
 II/ III/ IV 12 4.4 ± 4.9 
* Differentiated, papillary or tubular adenocarcinoma; 
undifferentiated, poorly differentiated, mucinous adeno-
carcinoma or signet-ring cell carcinoma.
† T1, tumor has invaded the lamina propria or submucosa; 
T2, tumor has invaded the muscularis propria or subse-
rosa; T3, tumor has penetrated the serosa; T4, tumor has 
invaded adjacent organs.
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CSFE labeling and proliferation assay
 
Cell proliferation was determined using carboxy-
fluorescein succinimidyl ester (CFSE) dilution as-
says.  CD4+ T cells were positively selected with 
anti-CD4 microbeads.  For staining with CFSE 
(Invitrogen, Carlsbad, CA), CD4+ T cells at 1 × 106 
cells/mL in phosphate-buffered solution were incu-
bated with 2 μM CFSE for 10 min at 37˚C.  Stain-
ing was terminated by adding RPMI 1640 contain-
ing 10% human AB serum (Gemini Bio-Products) 
at 4˚C, followed by 1 wash with phosphate-buffered 
solution.  The CFSE-labeled CD4+ T cells were 
seeded in anti-CD3 antibody-coated 96-well plates 
(3 × 105 cells/well; Nunc A/S, Roskilde, Denmark). 
In other experiments, CD14+ cells were depleted of 
other cells using anti-CD3, anti-CD16, anti-CD19, 
anti-CD56 and anti-glycophorin A microbeads 
(Miltenyi, Gladbach, Germany) and sorted based 
on their CD14+B7-H4+ or CD14+B7-H4– pheno-
types.  Next, either B7-H4+ or B7-H4– monocytes 
were added to CD4+ T cells at a ratio of 1:5.  The 
CD4+ T cells were profiled by CFSE labeling after 
5 days of incubation.  Unstained cells were in-
cluded in all experiments and were used to set the 
compensations on the flow cytometer.  
 
Regulation of B7-H4 expression
 
PBMCs (5 × 106) were cultured for different times 
with cancer cells, cell-free malignant ascites or se-
rum obtained from gastric cancer patients in 6-well 
plates.  After each period of coculture (12, 24 and 
48 h), PBMCs were harvested and analyzed for 
their B7-H4 expression and supernatants were ob-
tained after centrifuging at 300 × g for 5 min. 
 
Statistical analysis
 
The statistical significance of differences between 
2 groups was determined by the paired t-test or 
Mann-Whitney U-test.  Correlations were analyzed 
by the Spearman rank correlation coefficient test. 
The accepted level of significance was P < 0.05. 
The GraphPad Prism software (GraphPad Soft-
ware, La Jolla, CA) was used for all statistical 
analyses.
 
 
Results
 
B7-H4 expression on circulating monocytes 
and tumor-associated macrophages in pa-
tients with gastric cancer
 
First, we determined the B7-H4 expression on 
circulating monocytes from the normal controls 
(n = 18) and gastric cancer patients (n = 43).  The 
B7-H4 expression was significantly higher on cir-
culating monocytes from the gastric cancer patients 
than on those from the normal controls (4.9 ± 4.8% 
versus 2.0 ± 1.4%, P = 0.013; Fig. 1).  Table 1 shows 
the correlations between the B7-H4 expression on 
circulating monocytes and various clinicopatho-
logic factors.  The circulating monocytes from ad-
vanced gastric cancer patients exhibited higher B7-
Fig. 1.  B7-H4 expression on circulating monocytes.
 a: Representative FACS data for B7-H4 expression on 
circulating monocytes in the normal controls and 
gastric cancer patients. 
b: B7-H4 expression is significantly higher on circulat-
ing monocytes from the gastric cancer patients than 
on those from the normal controls (P = 0.013).  
[  ], number of subjects.  FACS, fluorescence-activated 
cell sorting.
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H4 expression than those from early gastric cancer 
patients (7.4 ± 5.7% versus 2.9 ± 2.1%, P = 0.0008). 
The B7-H4 expression was significantly higher in 
patients with lymphatic invasion than in patients 
without lymphatic invasion (5.7 ± 5.1% versus 2.4 ± 
1.4%, P = 0.03).  Moreover, significantly higher B7-
H4 expression was observed in patients with venous 
invasion than in patients without venous invasion 
(6.1 ± 5.2% versus 2.4 ± 1.3%, P = 0.015).  These 
findings indicate that increased B7-H4 expression 
on circulating monocytes is closely correlated with 
disease progression.  
 Next, we determined the B7-H4 expression 
on tumor-associated macrophages obtained from 
gastric cancer tissues.  The B7-H4 expression was 
significantly higher on tumor-associated mac-
rophages in the gastric cancer tissues than on cir-
culating monocytes (13.3 ± 6.8% versus 2.5 ± 2.7%, 
P = 0.0011; Fig. 2).
B7-H1 expression on circulating mono-
cytes and tumor-associated macrophages 
and its relationship with B7-H4 expression 
in gastric cancer patients
 
B7-H1 is another inhibitory member of the B7 
family.  To clarify the correlation between B7-H1 
expression and B7-H4 expression on circulating 
monocytes and tumor-associated macrophages, 
we determined the B7-H1 expression in the gastric 
cancer patients and normal controls.  The B7-H1 
expression was significantly higher on circulating 
monocytes from the gastric cancer patients than on 
those from the normal controls (15.2 ± 10.0% ver-
Fig. 2.  B7-H4 expression on 
tumor-associated macrophag-
es is significantly higher in 
gastric cancer tissues than on 
circulating monocytes (P = 
0.0011). 
sus 4.7 ± 2.3%, P < 0.0001; Fig. 3).  Furthermore, 
the B7-H1 expression was significantly higher on 
tumor-associated macrophages in the gastric cancer 
tissues than on circulating monocytes (18.4 ± 7.6% 
versus 9.5 ± 6.6%, P = 0.0042; Fig. 4).  Next, we 
analyzed the correlation between B7-H1 expression 
and B7-H4 expression and found that B7-H4 ex-
pression was closely correlated with B7-H1 expres-
sion in both the peripheral blood samples (r = 0.62, 
P < 0.00001; Fig. 5a) and gastric cancer tissues 
(r = 0.65, P = 0.049; Fig. 5b).
Fig. 4.  B7-H1 expression is 
significantly higher on tumor-
associated macrophages in 
gastric cancer tissues than on 
circulating monocytes (P = 
0.0042). 
Fig. 3.  B7-H1 expression on circulating monocytes.
 a: Representative FACS data for B7-H1 expression on 
circulating monocytes from the normal controls and 
gastric cancer patients.
b: B7-H1 expression is significantly higher on circulat-
ing monocytes from the gastric cancer patients than 
on those from the normal controls (P < 0.0001).  
[  ], number of subjects.  FACS, fluorescence-activated 
cell sorting.
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B7-H4 expression and HLA-DR expression 
on monocytes/macrophages in gastric can-
cer patients
 
Kuang et al. observed that monocytes in the peritu-
moral stroma had an activated phenotype with in-
creased expressions of HLA-DR, CD80 and CD86 
(Kuang et al., 2009).  Furthermore, they found 
significant correlations between the numbers of B7-
H1+ and HLA-DRhigh monocytes in hepatocellular 
carcinoma tissues.  Therefore, we determined the 
HLA-DR expression on monocytes/macrophages to 
investigate whether the same phenomenon was ob-
served in gastric cancer patients.  Significant cor-
relations between B7-H4 expression and HLA-DR 
expression were found on both circulating mono-
cytes (Fig. 6a) and tumor-associated macrophages 
(Fig. 6b).
 
B7-H4+ monocytes/macrophages exhibit an 
immunosuppressive phenotype
 
To examine the immunosuppressive function of B7-
H4+ monocytes/macrophages, we sorted B7-H4+ 
monocytes and cocultured the isolated cells with 
CD4+ T cells in anti-CD3 antibody-coated wells. 
CFSE assays revealed that B7-H4+ monocytes sup-
pressed the proliferation of CD4+ T cells compared 
with B7-H4– monocytes (Fig. 7a).  Furthermore, 
B7-H4+ monocytes significantly suppressed IFN-
gamma secretion by CD4+ T cells compared with 
B7-H4– monocytes (750 ± 623 ng/mL versus 996 ± 
689 ng/mL) (Fig. 7b).
 
Decreased B7-H4 expression on circulating 
monocytes from gastric cancer patients af-
ter complete surgical removal of the tumor
 
B7-H4 expression was detected on 7.9 ± 6.9% and 
2.8 ± 1.3% of monocytes (n = 12) before surgery 
and after surgery (1 month later), respectively, 
and this difference was statistically significant 
(P = 0.029; Fig. 8).
 
Fig. 5.  B7-H4 expression is closely correlated with B7-
H1 expression in both peripheral blood samples (r = 0.62, 
P < 0.0001) and gastric cancer tissues (r = 0.65, P = 0.049).
 
Fig. 6.  There are significant correlations between B7-H4 
expression and HLA-DR expression on circulating mono-
cytes (r = 0.54, P = 0.0008) and tumor-associated mac-
rophages (r = 0.88, P = 0.0072).  MFI, mean fluorescence 
intensity.
Fig. 7.  Immunosuppressive effects of B7-H4+ monocytes 
on CD4+ T cells.
 a: B7-H4+ monocytes suppress the proliferation of 
CD4+ T cells compared with B7-H4– monocytes, as 
evaluated by CFSE assays. 
b: B7-H4+ monocytes significantly suppress IFN-
gamma secretion by CD4+ T cells compared with 
B7-H4– monocytes (P = 0.023).  
CFSE, carboxyfluorescein succinimidyl ester. 
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Gastric cancer cell lines induce B7-H4 ex-
pression on monocytes
 
Finally, we carried out experiments using gastric 
cancer cell lines to examine the effects of cancer 
cells on B7-H4 expression.  We used 2 gastric can-
cer cell lines, MKN-45 and MKN-74.  As shown 
in Fig. 9, cocultures of the gastric cancer cell lines 
and PBMCs resulted in remarkable increases in B7-
H4 expression on monocytes.  This phenomenon 
was not observed when PBMCs were cultured in 
the presence of supernatants from the 2 gastric can-
cer cell lines.  Moreover, upregulation of B7-H4 ex-
pression was not observed in the presence of serum 
or ascites obtained from the gastric cancer patients. 
These results indicate that direct contacts between 
cancer cells and monocytes, but not soluble fac-
tors, are indispensable for B7-H4 overexpression on 
monocytes. 
 
 
Discussion
 
Immune suppressor cells are currently an area of 
active research interest.  The best-studied immuno-
suppressive cell population is the well-known, yet 
still relatively newly described, CD4+CD25+ regu-
latory T cells (Treg cells) (Sakaguchi et al., 2001; 
Shevach, 2002; von Herrath and Harrison, 2003). 
Human Treg cells (Woo et al., 2002; Curiel et al., 
2004) disable TAA-specific T-cell immunity (Zou, 
2005, 2006).  It has been shown that increased 
numbers of Treg cells are correlated with poor 
survival in hepatocellular carcinoma patients (Fu 
Fig. 9.  Cocultures of gastric cancer cell lines (MKN-45 
and MKN-74) and PBMCs exhibit a remarkable increase 
in B7-H4 expression on monocytes after 24 h.  Seen are 
mean fluorescence intensity (MFI) (mean ± SD).  Pre, be-
fore coculture. 
Fig. 8.  Increased B7-H4 ex-
pression on circulating mono-
cytes from gastric cancer pa-
tients is downregulated after 
complete surgical removal of 
the tumor (P = 0.029). 
et al., 2007) and ovarian cancer patients (Curiel et 
al., 2004).  Furthermore, myeloid-derived suppres-
sor cells (Ochoa et al., 2007; Hoechst et al., 2008) 
and CD4+NKG2D+ T cells (Groh et al., 2006) can 
diminish immunity against cancer cells in cancer 
patients.  These accumulating lines of evidence in-
dicate that immunosuppressive cells play important 
roles in tumor progression. 
 In the present study, we determined B7-H4 
expression on circulating monocytes and tumor-
associated macrophages in gastric cancer patients 
to clarify one of the key mechanisms responsible 
for immune evasion in gastric cancer.  B7-H4 ex-
pression was significantly higher on circulating 
monocytes from the gastric cancer patients than 
on those from the normal controls.  B7-H4 expres-
sion was closely related to the depth of invasion, 
as well as the presence of lymphatic and venous 
invasion.  Furthermore, B7-H4 expression was sig-
nificantly higher on tumor-associated macrophages 
in the gastric cancer tissues than on circulating 
monocytes.  The B7-H4+ circulating monocytes 
exhibited an immunosuppressive phenotype that 
suppressed CD4+ T-cell proliferation and IFN-
gamma secretion by CD4+ T cells.  Therefore, B7-
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H4+ circulating monocytes and tumor-associated 
macrophages may be related to immune evasion in 
gastric cancer patients.
 In addition to B7-H4, another member of the 
B7 family, B7-H1, is also selectively expressed by 
various cellular components in the tumor microen-
vironment and has been reported to be related to 
immune evasion in cancer patients (Dong et al., 
2002; Curiel et al., 2003).  In the present study, B7-
H1 expression was also significantly higher on cir-
culating monocytes from the gastric cancer patients 
than on those from the normal controls.  Further-
more, B7-H1 expression was significantly higher 
on tumor-associated macrophages in the gastric 
cancer tissues than on circulating monocytes.  The 
B7-H1 expression on circulating monocytes and 
tumor-associated macrophages was correlated 
with their HLA-DR expression, indicating that B7-
H1+ circulating monocytes and tumor-associated 
macrophages show activated phenotypes (data not 
shown).  These findings are consistent with those in 
a previous report (Kuang et al., 2009).  Of interest 
is that B7-H4 expression on circulating monocytes 
and tumor-associated macrophages was also cor-
related with their HLA-DR expression.  Moreover, 
B7-H4 expression was closely correlated with B7-
H1 expression in both peripheral blood samples 
and gastric cancer tissues.  These findings indicate 
that circulating monocytes and tumor-associated 
macrophages were activated and that both B7-
H1 and B7H4 expressions were upregulated as a 
result of this activation in gastric cancer patients. 
To the best of our knowledge, this is the first study 
to demonstrate overexpression of B7-H1 and B7-
H4 on circulating monocytes and tumor-associated 
macrophages in gastric cancer patients.
 Previous reports have demonstrated that 
upregulation of B7-H1 and B7-H4 is related to 
soluble factors, such as IL-6, IL-10 and TNF-alpha 
(Kryczek et al., 2006; Kuang et al., 2009).  How-
ever, serum and ascites obtained from the gastric 
cancer patients did not affect B7-H4 expression on 
monocytes in the present study (data not shown). 
Furthermore, supernatants obtained from 2 gastric 
cancer cell lines also did not affect B7-H4 expres-
sion on monocytes (data not shown).  These find-
ings indicate that soluble factors are not related to 
the upregulation of B7-H4 observed in the present 
study.  On the other hand, Kryczek et al. showed 
that upregulation of B7-H4 expression was correlat-
ed with the presence of Treg cells (Kryczek et al., 
2007).  Therefore, we determined the frequencies 
of Foxp3+ Treg cells in our blood and cancer tis-
sue samples and found no correlation between B7-
H4 expression on monocytes/macrophages and the 
frequency of Foxp3+ Treg cells (data not shown). 
In the present study, we observed remarkable up-
regulation of B7-H4 expression on macrophages 
in cancer tissues compared with peripheral blood 
samples.  Furthermore, a significant decrease in 
B7-H4 expression on circulating monocytes from 
gastric cancer patients was observed after complete 
surgical removal of the tumor.  These findings sug-
gest the possibility that cancer cells themselves 
may affect the B7-H4 overexpression on mono-
cytes and macrophages in gastric cancer patients. 
In fact, cocultures of gastric cancer cell lines and 
monocytes induced upregulation of B7-H4 expres-
sion on monocytes.  Since the supernatants from 
the 2 gastric cancer cell lines did not affect B7-H4 
expression, it is likely that direct contacts between 
cancer cells and monocytes/macrophages are indis-
pensable for the upregulation of B7-H4 expression 
on monocytes/macrophages.  Further investiga-
tions to clarify which molecules on tumor cells are 
related to the upregulation of B7-H4 expression on 
monocytes/macrophages are urgently required.
 Since monocytes/macrophages are closely 
related to immune evasion, they are important 
targets for cancer immunotherapy.  In this regard, 
Hagemann et al. showed that macrophages are 
polarized via IL-1R and MyD88 to an immuno-
suppressive “alternative” phenotype that requires 
IkappaB kinase beta-mediated nuclear factor 
(NF)-kappa B activation (Hagemann et al., 2008). 
When NF-kappa B signaling is specifically inhib-
ited in tumor-associated macrophages, the cells 
become cytotoxic toward tumor cells and switch 
to a “classically” activated phenotype of interleu-
kin (IL)-12high and MHC IIhigh, but IL-10low and 
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arginase-1low.  Targeting NF-kappa B signaling in 
tumor-associated macrophages also promotes the 
regression of advanced tumors in vivo by inducing 
macrophage tumoricidal activity and activating the 
antitumor activity through IL-12-dependent NK 
cell recruitment.  Furthermore, Luo et al. demon-
strated that DNA vaccines targeting legumain, a 
member of the asparaginyl endopeptidase family 
that functions as a stress protein, induce a robust 
CD8+ T-cell response against tumor-associated 
macrophages, which dramatically reduced their 
density in tumor tissues and markedly suppressed 
tumor growth and metastasis in a murine model 
(Luo et al., 2006).  These findings show that target-
ing of tumor-associated macrophages is attractive 
and effective for anticancer strategies.  Since B7-
H1+ and B7-H4+ monocytes/macrophages with 
immunosuppressive properties are increased in 
gastric cancer patients, targeting B7-H1+ and B7-
H4+ monocytes/macrophages may provide a break-
through in the treatment of gastric cancer.
 In conclusion, B7-H1+ and B7-H4+ circulat-
ing monocytes and tumor-associated macrophages 
with immunosuppressive activity were increased in 
gastric cancer patients.  This phenomenon may be 
one of the key mechanisms responsible for immune 
evasion in gastric cancer patients.  Therefore, tar-
geting B7-H1+ and B7-H4+ monocytes/macrophag-
es may provide a breakthrough in the treatment 
of gastric cancer.  Further investigations to clarify 
which molecules are related to the upregulation of 
B7-H4 expression on monocytes/macrophages are 
urgently required.
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